These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28783812)

  • 1. Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab.
    Hernandez I
    JAMA Intern Med; 2017 Sep; 177(9):1388-1390. PubMed ID: 28783812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 Inhibitors: A Technology Worth Paying For?
    Weintraub WS; Gidding SS
    Pharmacoeconomics; 2016 Mar; 34(3):217-20. PubMed ID: 26689785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
    Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
    JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases.
    Shah P
    Curr Cardiol Rep; 2018 May; 20(7):51. PubMed ID: 29779055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.
    Schulman KA; Balu S; Reed SD
    N Engl J Med; 2015 Oct; 373(17):1591-3. PubMed ID: 26444460
    [No Abstract]   [Full Text] [Related]  

  • 6. Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals.
    Blumenthal DM; Goldman DP; Jena AB
    Ann Intern Med; 2017 Feb; 166(3):219-220. PubMed ID: 27951598
    [No Abstract]   [Full Text] [Related]  

  • 7. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.
    Hess PL; Kennedy K; Cowherd M; Virani SS; Masoudi FA; Navar AM; Yeh RW; Ho PM; Maddox TM
    Am Heart J; 2018 Jan; 195():151-152. PubMed ID: 29224643
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
    Shah P; Glueck CJ; Jetty V; Goldenberg N; Rothschild M; Riaz R; Duhon G; Wang P
    Lipids Health Dis; 2016 Aug; 15(1):132. PubMed ID: 27538393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans.
    Kazi DS; Lu CY; Lin GA; DeJong C; Dudley RA; Chen R; Tseng CW
    JAMA Cardiol; 2017 Oct; 2(10):1164-1166. PubMed ID: 28903137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A safety evaluation of evolocumab.
    Roth EM
    Expert Opin Drug Saf; 2018 Jan; 17(1):99-106. PubMed ID: 28988500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 inhibitors and managing cost in the managed care setting.
    Stadler SL; Cook TJ
    Am J Manag Care; 2017 Jun; 23(9 Suppl):S149-S155. PubMed ID: 28978220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia.
    Schmitz J; Gouni-Berthold I
    Curr Pharm Des; 2017; 23(10):1484-1494. PubMed ID: 28137217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).
    Elbitar S; Khoury PE; Ghaleb Y; Rabès JP; Varret M; Seidah NG; Boileau C; Abifadel M
    Expert Opin Ther Pat; 2016 Dec; 26(12):1377-1392. PubMed ID: 27359211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review.
    Janković SM; Tešić D; Anđelković J; Kostić M
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):461-474. PubMed ID: 30014724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alirocumab's Price Reduction.
    Dhruva SS; Ross JS; Desai NR
    Circulation; 2018 Oct; 138(15):1502-1504. PubMed ID: 30354510
    [No Abstract]   [Full Text] [Related]  

  • 20. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
    Wang Y; Liu ZP
    Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.